{"filing":{"accession_number":"0001493152-26-032407","cik":"0001849296","ticker":"OKYO","company_name":"OKYO Pharma Ltd","form":"6-K","filing_date":"2026-07-08","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1849296/000149315226032407/form6-k.htm"},"events":[{"id":16586,"run_id":14817,"accession_number":"0001493152-26-032407","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This exhibit announces positive FDA Type D meeting feedback validating OKYO's regulatory and clinical development pathway for urcosimod, acceleration into a global Phase 3 pivotal trial (NEPTUNE), and plans to seek FDA Breakthrough Therapy Designation. While not a discrete M\u0026A, financing, or governance event, this represents a material operational and strategic milestone—FDA alignment on trial design and potential single-trial registration pathway materially de-risks the clinical development program and accelerates the path to potential commercialization for a lead candidate in a disease with no approved therapies.","company_name":"OKYO Pharma Ltd","ticker":"OKYO","filing_date":"2026-07-08","form":"6-K","submitted_at":null,"items":[{"id":14732,"accession_number":"0001493152-26-032407","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces positive FDA Type D meeting feedback validating OKYO's regulatory and clinical development pathway for urcosimod, acceleration into a global Phase 3 pivotal trial (NEPTUNE), and plans to seek FDA Breakthrough Therapy Designation. While not a discrete M\u0026A, financing, or governance event, this represents a material operational and strategic milestone—FDA alignment on trial design and potential single-trial registration pathway materially de-risks the clinical development program and accelerates the path to potential commercialization for a lead candidate in a disease with no approved therapies.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:02:37.582202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14732,"accession_number":"0001493152-26-032407","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This exhibit announces positive FDA Type D meeting feedback validating OKYO's regulatory and clinical development pathway for urcosimod, acceleration into a global Phase 3 pivotal trial (NEPTUNE), and plans to seek FDA Breakthrough Therapy Designation. While not a discrete M\u0026A, financing, or governance event, this represents a material operational and strategic milestone—FDA alignment on trial design and potential single-trial registration pathway materially de-risks the clinical development program and accelerates the path to potential commercialization for a lead candidate in a disease with no approved therapies.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:02:37.582202+00:00","company_name":"OKYO Pharma Ltd","ticker":"OKYO","filing_date":"2026-07-08"}]}